Gilead's shares rose 1.3% to $62.30, while Merck was up nearly 2% at $76.08. It was also shown to stand up against variants first reported in the U.K., South Africa, Brazil, California, New York and India. Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles. 1.7 million new HIV infections were reported globally in 2019 and 38 million people were living with HIV, according to the World Health Organization. "The market will infer that GSK and ViiV are left out in the cold here, supporting our long-standing concerns over the longer term outlook for GSK's HIV franchise," Citi analyst Andrew Baum said.
downloaded shares in Argentina are up at 199 not 250 thousand.
( z0 up :ARG1 ( z1 share :ARG1-of ( z2 down ) :location ( z3 country :name ( z4 name :op "Argentina" ) ) ) :ARG1-of ( z5 instead-of :ARG2 ( z6 up :ARG1 z1 :ARG2 250000 :polarity - ) ) :ARG2 199 )
(z0 / up-02
    :ARG1 (z1 / share
              :ARG1-of (z2 / down-03)
              :location (z3 / country
                            :name (z4 / name
                                      :op1 "Argentina")))
    :ARG1-of (z5 / instead-of-91
                 :ARG2 (z6 / up-02
                           :ARG1 z1
                           :ARG2 250000
                           :polarity -))
    :ARG2 199)
downloaded shares in Argentina are up at 199 not 250 thousand .
z1 :ARG1-of z2
z1 :location z3
z3 :name z4
z4 :op1 3
z0 :ARG1 z1
z6 :ARG1 z1
z0 :ARG2 1
z5 :ARG2 z6
z0 :ARG1-of z5
z6 :polarity 0
z6 :ARG2 2